Opus Genetics reports positive OPGx-BEST1 Phase 1/2 cohort 1 data
OPGx-BEST1 showed a favorable safety and tolerability profile in cohort 1, with no serious adverse events or dose-limiting toxicities observed. All five participants showed clinically meaningful visual function improvement.
OPGx-BEST1 showed a favorable safety and tolerability profile, with no serious adverse events or dose-limiting toxicities observed. All five participants showed clinically meaningful improvement in visual function, while structural improvements were observed in four participants. The FDA aligned on ≥3.